β-Blocker use in systolic heart failure and dilated cardiomyopathy

Journal of Clinical Pharmacology

Volumn 37, Issue 1, 1997, Pages 7-19

  Hash II, Thomas W ^a   Prisant, L Michael ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LABETALOL; METOPROLOL; NEBIVOLOL; NORADRENALIN; XAMOTEROL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE TOLERANCE; HEART DILATATION; HUMAN; MORTALITY; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; REVIEW;

EID: 0030939618     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009703700103     Document Type: Review

References (73)

1. Domanski MJ, Eichhorn EJ: Beta blockade in congestive heart failure - the need for a definitive study. Am J Cardiol 1994; 73:597-599.
2. Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22(suppl A):6A-13A.
3. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
4. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. Baker DW, Konstam MA, Bottorff M, Pitt B: Management of heart failure: I. Pharmacologic treatment. JAMA 1994;272:1361-1366.
7. Waagstein F, Hjalmarson Å, Varnauskas E, Wallentin I: Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
8. Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I: Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-1376.
9. Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I: Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134-142.
10. Swedberg K, Hjalmarson Å. Waagslein F, Wallentin I: Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-133.
11. Bristow MR: Pathophysiology and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71(suppl):12C-22C.
12. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-438.
13. Colin JN: Vasodilators in heart failure: conclusions from V-HeFT II and rationale for V-HeFT III. Drugs 1994;47(suppl 4):47-58.
14. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-1161.
15. Cleland JGF, Puri S: How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodeling, resetting, or sudden death? Br Heart J 1994;72 (suppl):81-86.
16. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, et al: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88(part 1):2277-2283.
17. Andersson B, Hamm C, Persson S, Wikström G, Sinagra G, Hialmarson Å, Waagstein F: Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 1994;23:1397-1404.
18. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, et al: Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100.
19. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al: Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
20. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, et al: Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-483.
21. Lipicky RJ, Packer M: Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993;22(suppl A):179A-184A.
22. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson Å: Long-term β-blockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80:551-563.
23. Swedberg K: Exercise testing in heart failure: a critical review. Drags 1994;47(suppl 4):14-24.
24. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G. Tristani F, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
25. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Hartson WE, Tristani F, et al: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
26. Metra M, Nardi M, Giubbini R, Dei Gas L: Effects of short-and long-term carvedilol administration on rest and exercise hemodvnamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1078-1687.
27. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
28. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al: Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632-1642.
29. Gilbert EM, Olsen SL, Renlund DG, Bristow MR: Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993:71(suppl):23C-29C.
30. Francis GS: The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J 1989;118:642-648.
31. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB: Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-490.
32. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, et al: Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995;76:1271-1276.
33. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-950.
34. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML: Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75(suppl):IV-80-IV-92.
35. Floras JS: Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993;22(suppl A):72A-84A.
36. Packer M: How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993;71(suppl):3C-11C.
37. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
38. Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN: Predicting survival for an individual with congestive heart failure using plasma norepinephrine concentration. Am Heart J 1987; 114:148-152.
39. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relationship to mortality. Circulation 1990;82:1730-1736.
40. Cohn JN, Judd DL: Sequential neurohormonal response to felodipine in enalapril-treated heart failure: V-HeFT III (abstract). J Am Coll Cardiol 1996;27:141A.
41. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A: Plasma norepinephrine, plasma renin activity, and conoestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(suppl VI):VI-40-VI-48.
42. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in Severe Heart Failure. Lancet 1990;336:1-6.
43. Franciosa JA: Why patients with heart failure die: hemodynamic and functional determinants of survival. Circulation 1987;75(suppl IV):IV-20-IV-26.
44. Kaye DM, Lefkovitz J, Jennings GL, Bergin P, Broughton A. Esler MD: Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26:1257-1263.
45. Massie BM, Conway M: Survival of patients with congestive heart failure: past present, and future prospects. Circulation 1987;75(suppl IV):IV-11-IV-19.
46. Held P: Effects of beta blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects. Am J Cardiol 1993;71(suppl):39C-44C.
47. Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510.
48. Kennedy HL, Brooks MM, Barker AH, Bergstrand R, Huther ML, Beanlands DS, et al: Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994;74:674-680.
49. Lichstein E, Hager WD, Gregory JJ, Fleiss JL, Rolnitzky LM, Bisser J Jr: Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group. J Am Coll Cardiol 1990;16:1327-1332.
50. Di Lenarda A, Secoli G, Perkan A, Gregori D, Lardieri G, Pinamonti B, et al: Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group. Br Heart J 1994; 72(suppl):S46-S51.
51. Cruickshank JM: The xamoterol experience in the treatment of heart failure. Am J Cardiol 1993;71(suppl):61C-64C.
52. Fowler MB: Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol 1993; 71(suppl):45C-53C.
53. Ikram H, Fitzpatrick D: Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981;ii:490-493.
54. Eichhorn EJ: The paradox of β-adrenergic blockade for the management of congestive heart failure. Am J Med 1992;92:527-538.
55. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
56. CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
57. Bristow MR, Gilbert EM. Abraham WT, Adams KF, Fowler MB, Hershberger R, et al: Multicenter Oral Carvedilol Heart failure Assessment (MOCHA): a six-month dose-response evaluation in Class II-IV patients. Circulation 1995;92(suppl I):I-142.
58. Colucci WS, Packer M, Bristow MR, Cohn JN, Fowler MB, Gilbert EM, et al: Carvedilol inhibits clinical progression in patients with mild heart failure. Circulation 1995;92(suppl I):I-395.
59. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM: Effect of carvedilol on the survival of patients with chronic heart failure. Circulation 1995;92(suppl I):I-142.
60. Cohn JN, Fowler MB, Bristow MA, Colucci WS, Gilbert EM, Kinal V, et al: Effect of carvedilol in severe chronic heart failure. J Am Coll Cardiol 1996;27(suppl A):169A.
61. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
62. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-1456.
63. The BEST Steering Committee: Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995;75:1220-1223.
64. Currie PJ, Kelly MJ, McKenzie A, Harper RW, Lim YL, Federman J, et al: Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203-209.
65. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholomew M: A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-475.
66. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM: Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72:536-546.
67. Leung WL, Lau CP, Wong CK, Cheng CH, Tai YT, Lim SP: Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990;119:884-890.
68. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al: Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-229.
69. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML: Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603-607.
70. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al: Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
71. Paolisso G, Gambardella A, Marrazzo G, Verza M, Teasuro P, Varricchio M, D'Onofrio F: Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992;123:103-110.
72. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
73. Packer M, Colucci WS, Sackner-Bernstein J, Liang C, Goldschef DA, Freeman I, et al: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise tolerance in chronic heart failure: results of the PRECISE Trial. Circulation 1995; 92(suppl I):I-143.